nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.296	0.428	CbGbCtD
Erlotinib—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.274	0.395	CbGbCtD
Erlotinib—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.122	0.177	CbGbCtD
Erlotinib—Nephritis—Riluzole—amyotrophic lateral sclerosis	0.00808	0.0661	CcSEcCtD
Erlotinib—LTK—tongue—amyotrophic lateral sclerosis	0.00753	0.0855	CbGeAlD
Erlotinib—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00498	0.0408	CcSEcCtD
Erlotinib—ULK3—tongue—amyotrophic lateral sclerosis	0.00409	0.0465	CbGeAlD
Erlotinib—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.00397	0.0325	CcSEcCtD
Erlotinib—Ileus—Riluzole—amyotrophic lateral sclerosis	0.0039	0.0319	CcSEcCtD
Erlotinib—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.0039	0.0319	CcSEcCtD
Erlotinib—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.0039	0.0319	CcSEcCtD
Erlotinib—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00303	0.0248	CcSEcCtD
Erlotinib—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00276	0.0226	CcSEcCtD
Erlotinib—Melaena—Riluzole—amyotrophic lateral sclerosis	0.0027	0.0221	CcSEcCtD
Erlotinib—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00239	0.0196	CcSEcCtD
Erlotinib—MAP2K5—hindbrain—amyotrophic lateral sclerosis	0.00217	0.0247	CbGeAlD
Erlotinib—Vandetanib—VEGFA—amyotrophic lateral sclerosis	0.00214	1	CrCbGaD
Erlotinib—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.002	0.0164	CcSEcCtD
Erlotinib—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00186	0.0153	CcSEcCtD
Erlotinib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00182	0.0149	CcSEcCtD
Erlotinib—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00177	0.0145	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00177	0.0145	CcSEcCtD
Erlotinib—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00173	0.0142	CcSEcCtD
Erlotinib—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.0017	0.0139	CcSEcCtD
Erlotinib—ABL1—hindbrain—amyotrophic lateral sclerosis	0.00168	0.019	CbGeAlD
Erlotinib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00162	0.0133	CcSEcCtD
Erlotinib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00157	0.0128	CcSEcCtD
Erlotinib—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00155	0.0127	CcSEcCtD
Erlotinib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00154	0.0126	CcSEcCtD
Erlotinib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00154	0.0126	CcSEcCtD
Erlotinib—Depression—Riluzole—amyotrophic lateral sclerosis	0.00154	0.0126	CcSEcCtD
Erlotinib—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00152	0.0125	CcSEcCtD
Erlotinib—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0124	CcSEcCtD
Erlotinib—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0124	CcSEcCtD
Erlotinib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.0015	0.0123	CcSEcCtD
Erlotinib—AURKC—nervous system—amyotrophic lateral sclerosis	0.0015	0.017	CbGeAlD
Erlotinib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00146	0.012	CcSEcCtD
Erlotinib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00146	0.0119	CcSEcCtD
Erlotinib—AURKC—central nervous system—amyotrophic lateral sclerosis	0.00144	0.0163	CbGeAlD
Erlotinib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00139	0.0114	CcSEcCtD
Erlotinib—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00139	0.0113	CcSEcCtD
Erlotinib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00139	0.0113	CcSEcCtD
Erlotinib—JAK3—nervous system—amyotrophic lateral sclerosis	0.00139	0.0157	CbGeAlD
Erlotinib—EPHA6—nervous system—amyotrophic lateral sclerosis	0.00139	0.0157	CbGeAlD
Erlotinib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00137	0.0112	CcSEcCtD
Erlotinib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00136	0.0111	CcSEcCtD
Erlotinib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00136	0.0111	CcSEcCtD
Erlotinib—HIPK4—brain—amyotrophic lateral sclerosis	0.00134	0.0152	CbGeAlD
Erlotinib—JAK3—central nervous system—amyotrophic lateral sclerosis	0.00133	0.0151	CbGeAlD
Erlotinib—EPHA6—central nervous system—amyotrophic lateral sclerosis	0.00133	0.0151	CbGeAlD
Erlotinib—LTK—brain—amyotrophic lateral sclerosis	0.00132	0.015	CbGeAlD
Erlotinib—PIP4K2C—medulla oblongata—amyotrophic lateral sclerosis	0.00131	0.0149	CbGeAlD
Erlotinib—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00131	0.0107	CcSEcCtD
Erlotinib—JAK3—cerebellum—amyotrophic lateral sclerosis	0.0013	0.0148	CbGeAlD
Erlotinib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0106	CcSEcCtD
Erlotinib—MAP3K19—nervous system—amyotrophic lateral sclerosis	0.00126	0.0143	CbGeAlD
Erlotinib—ULK3—medulla oblongata—amyotrophic lateral sclerosis	0.00125	0.0142	CbGeAlD
Erlotinib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00125	0.0102	CcSEcCtD
Erlotinib—MAP2K5—brainstem—amyotrophic lateral sclerosis	0.00124	0.0141	CbGeAlD
Erlotinib—Chills—Riluzole—amyotrophic lateral sclerosis	0.00124	0.0102	CcSEcCtD
Erlotinib—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00124	0.0101	CcSEcCtD
Erlotinib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00122	0.01	CcSEcCtD
Erlotinib—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00994	CcSEcCtD
Erlotinib—MAP3K19—central nervous system—amyotrophic lateral sclerosis	0.00121	0.0138	CbGeAlD
Erlotinib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00988	CcSEcCtD
Erlotinib—TNK1—cerebellum—amyotrophic lateral sclerosis	0.0012	0.0136	CbGeAlD
Erlotinib—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00973	CcSEcCtD
Erlotinib—MKNK1—medulla oblongata—amyotrophic lateral sclerosis	0.00118	0.0134	CbGeAlD
Erlotinib—PIP4K2C—spinal cord—amyotrophic lateral sclerosis	0.00117	0.0133	CbGeAlD
Erlotinib—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00955	CcSEcCtD
Erlotinib—AURKC—brain—amyotrophic lateral sclerosis	0.00114	0.013	CbGeAlD
Erlotinib—ULK3—spinal cord—amyotrophic lateral sclerosis	0.00112	0.0127	CbGeAlD
Erlotinib—SLK—medulla oblongata—amyotrophic lateral sclerosis	0.00112	0.0127	CbGeAlD
Erlotinib—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00886	CcSEcCtD
Erlotinib—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00868	CcSEcCtD
Erlotinib—EPHA6—brain—amyotrophic lateral sclerosis	0.00106	0.012	CbGeAlD
Erlotinib—JAK3—brain—amyotrophic lateral sclerosis	0.00106	0.012	CbGeAlD
Erlotinib—Cough—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00862	CcSEcCtD
Erlotinib—MKNK1—spinal cord—amyotrophic lateral sclerosis	0.00105	0.012	CbGeAlD
Erlotinib—ABL1—embryo—amyotrophic lateral sclerosis	0.00105	0.0119	CbGeAlD
Erlotinib—FLT3—cerebellum—amyotrophic lateral sclerosis	0.00103	0.0117	CbGeAlD
Erlotinib—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00841	CcSEcCtD
Erlotinib—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00841	CcSEcCtD
Erlotinib—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00841	CcSEcCtD
Erlotinib—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00838	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00835	CcSEcCtD
Erlotinib—SLK—spinal cord—amyotrophic lateral sclerosis	0.000997	0.0113	CbGeAlD
Erlotinib—PIP4K2C—nervous system—amyotrophic lateral sclerosis	0.000987	0.0112	CbGeAlD
Erlotinib—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000985	0.00806	CcSEcCtD
Erlotinib—ABL2—cerebellum—amyotrophic lateral sclerosis	0.000982	0.0111	CbGeAlD
Erlotinib—Infection—Riluzole—amyotrophic lateral sclerosis	0.000978	0.00801	CcSEcCtD
Erlotinib—TNK1—brain—amyotrophic lateral sclerosis	0.000972	0.011	CbGeAlD
Erlotinib—Shock—Riluzole—amyotrophic lateral sclerosis	0.000969	0.00793	CcSEcCtD
Erlotinib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000966	0.0079	CcSEcCtD
Erlotinib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000964	0.00789	CcSEcCtD
Erlotinib—MAP3K19—brain—amyotrophic lateral sclerosis	0.000962	0.0109	CbGeAlD
Erlotinib—ABL1—brainstem—amyotrophic lateral sclerosis	0.00096	0.0109	CbGeAlD
Erlotinib—EGFR—cerebellum—amyotrophic lateral sclerosis	0.000958	0.0109	CbGeAlD
Erlotinib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000956	0.00783	CcSEcCtD
Erlotinib—PIP4K2C—central nervous system—amyotrophic lateral sclerosis	0.00095	0.0108	CbGeAlD
Erlotinib—ULK3—nervous system—amyotrophic lateral sclerosis	0.000942	0.0107	CbGeAlD
Erlotinib—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000939	0.00768	CcSEcCtD
Erlotinib—PIP4K2C—cerebellum—amyotrophic lateral sclerosis	0.000929	0.0105	CbGeAlD
Erlotinib—ULK3—central nervous system—amyotrophic lateral sclerosis	0.000907	0.0103	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000897	0.00734	CcSEcCtD
Erlotinib—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000891	0.00729	CcSEcCtD
Erlotinib—MKNK1—nervous system—amyotrophic lateral sclerosis	0.000887	0.0101	CbGeAlD
Erlotinib—ULK3—cerebellum—amyotrophic lateral sclerosis	0.000887	0.0101	CbGeAlD
Erlotinib—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000878	0.00719	CcSEcCtD
Erlotinib—MAP2K5—medulla oblongata—amyotrophic lateral sclerosis	0.000868	0.00986	CbGeAlD
Erlotinib—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000867	0.00709	CcSEcCtD
Erlotinib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000856	0.00701	CcSEcCtD
Erlotinib—MKNK1—central nervous system—amyotrophic lateral sclerosis	0.000854	0.0097	CbGeAlD
Erlotinib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00085	0.00696	CcSEcCtD
Erlotinib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000849	0.00695	CcSEcCtD
Erlotinib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000842	0.00689	CcSEcCtD
Erlotinib—Pain—Riluzole—amyotrophic lateral sclerosis	0.000842	0.00689	CcSEcCtD
Erlotinib—MKNK1—cerebellum—amyotrophic lateral sclerosis	0.000835	0.00948	CbGeAlD
Erlotinib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000805	0.00659	CcSEcCtD
Erlotinib—ABL2—brain—amyotrophic lateral sclerosis	0.000797	0.00905	CbGeAlD
Erlotinib—SLK—cerebellum—amyotrophic lateral sclerosis	0.00079	0.00897	CbGeAlD
Erlotinib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000778	0.00637	CcSEcCtD
Erlotinib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000778	0.00637	CcSEcCtD
Erlotinib—EGFR—brain—amyotrophic lateral sclerosis	0.000778	0.00884	CbGeAlD
Erlotinib—MAP2K5—spinal cord—amyotrophic lateral sclerosis	0.000774	0.00879	CbGeAlD
Erlotinib—PIP4K2C—brain—amyotrophic lateral sclerosis	0.000754	0.00857	CbGeAlD
Erlotinib—STK10—nervous system—amyotrophic lateral sclerosis	0.00073	0.00829	CbGeAlD
Erlotinib—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000724	0.00822	CbGeAlD
Erlotinib—ULK3—brain—amyotrophic lateral sclerosis	0.00072	0.00818	CbGeAlD
Erlotinib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000706	0.00578	CcSEcCtD
Erlotinib—STK10—central nervous system—amyotrophic lateral sclerosis	0.000703	0.00798	CbGeAlD
Erlotinib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000697	0.0057	CcSEcCtD
Erlotinib—STK10—cerebellum—amyotrophic lateral sclerosis	0.000687	0.0078	CbGeAlD
Erlotinib—MKNK1—brain—amyotrophic lateral sclerosis	0.000678	0.0077	CbGeAlD
Erlotinib—SLCO2B1—medulla oblongata—amyotrophic lateral sclerosis	0.000675	0.00767	CbGeAlD
Erlotinib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000674	0.00551	CcSEcCtD
Erlotinib—ABL1—medulla oblongata—amyotrophic lateral sclerosis	0.00067	0.0076	CbGeAlD
Erlotinib—MAP2K5—nervous system—amyotrophic lateral sclerosis	0.000652	0.00741	CbGeAlD
Erlotinib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000651	0.00533	CcSEcCtD
Erlotinib—SLK—brain—amyotrophic lateral sclerosis	0.000642	0.00729	CbGeAlD
Erlotinib—ORM1—spinal cord—amyotrophic lateral sclerosis	0.000628	0.00714	CbGeAlD
Erlotinib—MAP2K5—central nervous system—amyotrophic lateral sclerosis	0.000628	0.00713	CbGeAlD
Erlotinib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000626	0.00512	CcSEcCtD
Erlotinib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000621	0.00508	CcSEcCtD
Erlotinib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00062	0.00508	CcSEcCtD
Erlotinib—Headache—Riluzole—amyotrophic lateral sclerosis	0.000617	0.00505	CcSEcCtD
Erlotinib—MAP2K5—cerebellum—amyotrophic lateral sclerosis	0.000614	0.00697	CbGeAlD
Erlotinib—SLCO2B1—spinal cord—amyotrophic lateral sclerosis	0.000602	0.00684	CbGeAlD
Erlotinib—ABL1—spinal cord—amyotrophic lateral sclerosis	0.000597	0.00678	CbGeAlD
Erlotinib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000585	0.00479	CcSEcCtD
Erlotinib—STK10—brain—amyotrophic lateral sclerosis	0.000558	0.00634	CbGeAlD
Erlotinib—ORM1—nervous system—amyotrophic lateral sclerosis	0.00053	0.00601	CbGeAlD
Erlotinib—ORM1—central nervous system—amyotrophic lateral sclerosis	0.00051	0.00579	CbGeAlD
Erlotinib—SLCO2B1—nervous system—amyotrophic lateral sclerosis	0.000508	0.00576	CbGeAlD
Erlotinib—ABL1—nervous system—amyotrophic lateral sclerosis	0.000503	0.00571	CbGeAlD
Erlotinib—MAP2K5—brain—amyotrophic lateral sclerosis	0.000499	0.00566	CbGeAlD
Erlotinib—SLCO2B1—central nervous system—amyotrophic lateral sclerosis	0.000489	0.00555	CbGeAlD
Erlotinib—ABL1—central nervous system—amyotrophic lateral sclerosis	0.000484	0.0055	CbGeAlD
Erlotinib—SLCO2B1—cerebellum—amyotrophic lateral sclerosis	0.000478	0.00542	CbGeAlD
Erlotinib—ABL1—cerebellum—amyotrophic lateral sclerosis	0.000473	0.00538	CbGeAlD
Erlotinib—CYP1B1—nervous system—amyotrophic lateral sclerosis	0.000426	0.00484	CbGeAlD
Erlotinib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000422	0.0048	CbGeAlD
Erlotinib—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000415	0.00471	CbGeAlD
Erlotinib—CYP1B1—central nervous system—amyotrophic lateral sclerosis	0.00041	0.00466	CbGeAlD
Erlotinib—CYP1B1—cerebellum—amyotrophic lateral sclerosis	0.000401	0.00455	CbGeAlD
Erlotinib—SLCO2B1—brain—amyotrophic lateral sclerosis	0.000388	0.00441	CbGeAlD
Erlotinib—ABL1—brain—amyotrophic lateral sclerosis	0.000385	0.00437	CbGeAlD
Erlotinib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000377	0.00428	CbGeAlD
Erlotinib—ALB—brain—amyotrophic lateral sclerosis	0.000355	0.00403	CbGeAlD
Erlotinib—ABCB1—embryo—amyotrophic lateral sclerosis	0.000326	0.0037	CbGeAlD
Erlotinib—CYP1B1—brain—amyotrophic lateral sclerosis	0.000326	0.0037	CbGeAlD
Erlotinib—CYP1A1—nervous system—amyotrophic lateral sclerosis	0.000301	0.00342	CbGeAlD
Erlotinib—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000299	0.00339	CbGeAlD
Erlotinib—CYP1A1—central nervous system—amyotrophic lateral sclerosis	0.00029	0.00329	CbGeAlD
Erlotinib—CYP2C8—brain—amyotrophic lateral sclerosis	0.000249	0.00283	CbGeAlD
Erlotinib—ABCG2—brain—amyotrophic lateral sclerosis	0.000243	0.00275	CbGeAlD
Erlotinib—CYP1A1—brain—amyotrophic lateral sclerosis	0.00023	0.00261	CbGeAlD
Erlotinib—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000221	0.00251	CbGeAlD
Erlotinib—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000218	0.00247	CbGeAlD
Erlotinib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000213	0.00242	CbGeAlD
Erlotinib—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000209	0.00238	CbGeAlD
Erlotinib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000208	0.00236	CbGeAlD
Erlotinib—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000205	0.00232	CbGeAlD
Erlotinib—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000186	0.00211	CbGeAlD
Erlotinib—CYP2D6—brain—amyotrophic lateral sclerosis	0.000166	0.00189	CbGeAlD
Erlotinib—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000156	0.00178	CbGeAlD
Erlotinib—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000151	0.00171	CbGeAlD
Erlotinib—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000147	0.00167	CbGeAlD
Erlotinib—ABCB1—brain—amyotrophic lateral sclerosis	0.00012	0.00136	CbGeAlD
Erlotinib—JAK3—Immune System—C3—amyotrophic lateral sclerosis	3.53e-05	0.000371	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	3.52e-05	0.00037	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	3.49e-05	0.000366	CbGpPWpGaD
Erlotinib—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	3.47e-05	0.000364	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	3.47e-05	0.000364	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.46e-05	0.000364	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.44e-05	0.000361	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.42e-05	0.000359	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GSR—amyotrophic lateral sclerosis	3.42e-05	0.000359	CbGpPWpGaD
Erlotinib—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.42e-05	0.000359	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—VEGFA—amyotrophic lateral sclerosis	3.38e-05	0.000355	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PLB1—amyotrophic lateral sclerosis	3.37e-05	0.000354	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.37e-05	0.000354	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	3.36e-05	0.000353	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	3.36e-05	0.000353	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—FIG4—amyotrophic lateral sclerosis	3.33e-05	0.000349	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	3.33e-05	0.000349	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	3.33e-05	0.000349	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	3.3e-05	0.000346	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	3.29e-05	0.000345	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	3.27e-05	0.000343	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.25e-05	0.000341	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	3.24e-05	0.00034	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.23e-05	0.000339	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.23e-05	0.000339	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.21e-05	0.000337	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	3.19e-05	0.000335	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	3.19e-05	0.000334	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	3.13e-05	0.000329	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	3.13e-05	0.000329	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—TP53—amyotrophic lateral sclerosis	3.13e-05	0.000328	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.11e-05	0.000327	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GSR—amyotrophic lateral sclerosis	3.11e-05	0.000326	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—C3—amyotrophic lateral sclerosis	3.1e-05	0.000326	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	3.06e-05	0.000322	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	3.05e-05	0.00032	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	3.04e-05	0.000319	CbGpPWpGaD
Erlotinib—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	3.03e-05	0.000318	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.03e-05	0.000318	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.02e-05	0.000317	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—DAO—amyotrophic lateral sclerosis	3.01e-05	0.000316	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	3.01e-05	0.000316	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	3e-05	0.000315	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.95e-05	0.000309	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.95e-05	0.000309	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.94e-05	0.000309	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.93e-05	0.000307	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	2.88e-05	0.000302	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	2.87e-05	0.000301	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.85e-05	0.000299	CbGpPWpGaD
Erlotinib—ABL1—Immune System—SQSTM1—amyotrophic lateral sclerosis	2.84e-05	0.000299	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.84e-05	0.000298	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.83e-05	0.000297	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.82e-05	0.000296	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.81e-05	0.000295	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	2.76e-05	0.00029	CbGpPWpGaD
Erlotinib—EGFR—Disease—CST3—amyotrophic lateral sclerosis	2.76e-05	0.000289	CbGpPWpGaD
Erlotinib—MKNK1—Disease—PTGS2—amyotrophic lateral sclerosis	2.76e-05	0.000289	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.76e-05	0.000289	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	2.75e-05	0.000289	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.75e-05	0.000288	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.75e-05	0.000288	CbGpPWpGaD
Erlotinib—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	2.74e-05	0.000288	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	2.7e-05	0.000284	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.69e-05	0.000282	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.67e-05	0.000281	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ATF1—amyotrophic lateral sclerosis	2.67e-05	0.00028	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.66e-05	0.00028	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	2.66e-05	0.000279	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.65e-05	0.000279	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.65e-05	0.000279	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—C3—amyotrophic lateral sclerosis	2.65e-05	0.000278	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—IGF1—amyotrophic lateral sclerosis	2.65e-05	0.000278	CbGpPWpGaD
Erlotinib—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.64e-05	0.000277	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.63e-05	0.000276	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.62e-05	0.000275	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.61e-05	0.000273	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.58e-05	0.000271	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.56e-05	0.000269	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—amyotrophic lateral sclerosis	2.56e-05	0.000268	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.55e-05	0.000268	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—C3—amyotrophic lateral sclerosis	2.55e-05	0.000267	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CASP9—amyotrophic lateral sclerosis	2.54e-05	0.000267	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	2.53e-05	0.000266	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	2.51e-05	0.000263	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	2.49e-05	0.000262	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.48e-05	0.00026	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.47e-05	0.00026	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.44e-05	0.000256	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SQSTM1—amyotrophic lateral sclerosis	2.43e-05	0.000255	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.43e-05	0.000255	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	2.41e-05	0.000253	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	2.4e-05	0.000252	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—MMP9—amyotrophic lateral sclerosis	2.35e-05	0.000247	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.33e-05	0.000244	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.31e-05	0.000243	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.29e-05	0.00024	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.28e-05	0.00024	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.28e-05	0.000239	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ATF1—amyotrophic lateral sclerosis	2.28e-05	0.000239	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	2.27e-05	0.000238	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.26e-05	0.000237	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.24e-05	0.000235	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	2.23e-05	0.000234	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ERBB4—amyotrophic lateral sclerosis	2.17e-05	0.000228	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CASP9—amyotrophic lateral sclerosis	2.17e-05	0.000228	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	2.14e-05	0.000225	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.12e-05	0.000223	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.12e-05	0.000223	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—VEGFA—amyotrophic lateral sclerosis	2.11e-05	0.000222	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.11e-05	0.000221	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSR—amyotrophic lateral sclerosis	2.11e-05	0.000221	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	2.09e-05	0.00022	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	2.08e-05	0.000218	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	2.07e-05	0.000217	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.05e-05	0.000215	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.05e-05	0.000215	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD40LG—amyotrophic lateral sclerosis	2.04e-05	0.000215	CbGpPWpGaD
Erlotinib—EGFR—Disease—CASP9—amyotrophic lateral sclerosis	2e-05	0.00021	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.97e-05	0.000206	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	1.93e-05	0.000203	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	1.92e-05	0.000201	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	1.92e-05	0.000201	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.92e-05	0.000201	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	1.92e-05	0.000201	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.92e-05	0.000201	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.91e-05	0.000201	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.87e-05	0.000197	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.86e-05	0.000195	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB4—amyotrophic lateral sclerosis	1.86e-05	0.000195	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	1.83e-05	0.000192	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.82e-05	0.000191	CbGpPWpGaD
Erlotinib—ABL1—Immune System—C3—amyotrophic lateral sclerosis	1.81e-05	0.00019	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.79e-05	0.000188	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.77e-05	0.000185	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.76e-05	0.000184	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.76e-05	0.000184	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.76e-05	0.000184	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.75e-05	0.000183	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD40LG—amyotrophic lateral sclerosis	1.75e-05	0.000183	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.74e-05	0.000183	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.73e-05	0.000182	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.73e-05	0.000182	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.73e-05	0.000181	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	1.72e-05	0.00018	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB4—amyotrophic lateral sclerosis	1.72e-05	0.00018	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.69e-05	0.000178	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.69e-05	0.000177	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.68e-05	0.000176	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP9—amyotrophic lateral sclerosis	1.68e-05	0.000176	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	1.65e-05	0.000174	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.64e-05	0.000172	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.63e-05	0.000171	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.62e-05	0.00017	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	1.58e-05	0.000166	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	1.58e-05	0.000166	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.58e-05	0.000166	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	1.58e-05	0.000165	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.57e-05	0.000165	CbGpPWpGaD
Erlotinib—EGFR—Immune System—C3—amyotrophic lateral sclerosis	1.54e-05	0.000162	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.52e-05	0.00016	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.51e-05	0.000158	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	1.51e-05	0.000158	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.49e-05	0.000156	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.48e-05	0.000155	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.47e-05	0.000155	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.45e-05	0.000153	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.45e-05	0.000152	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.44e-05	0.000151	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.43e-05	0.00015	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.4e-05	0.000147	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.39e-05	0.000146	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.38e-05	0.000145	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.37e-05	0.000144	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.35e-05	0.000142	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.34e-05	0.000141	CbGpPWpGaD
Erlotinib—EGFR—Disease—APOE—amyotrophic lateral sclerosis	1.33e-05	0.000139	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—amyotrophic lateral sclerosis	1.31e-05	0.000137	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	1.31e-05	0.000137	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.3e-05	0.000137	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.28e-05	0.000134	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.26e-05	0.000132	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.23e-05	0.000129	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—APOE—amyotrophic lateral sclerosis	1.22e-05	0.000128	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.22e-05	0.000128	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.2e-05	0.000126	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.15e-05	0.000121	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.15e-05	0.00012	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—APOE—amyotrophic lateral sclerosis	1.14e-05	0.00012	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.13e-05	0.000119	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.12e-05	0.000118	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.1e-05	0.000116	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.1e-05	0.000116	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.08e-05	0.000113	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.04e-05	0.000109	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	1.04e-05	0.000109	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.04e-05	0.000109	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.01e-05	0.000106	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.98e-06	0.000105	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.91e-06	0.000104	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.85e-06	0.000103	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.83e-06	0.000103	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.35e-06	9.81e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.3e-06	9.76e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.29e-06	9.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—amyotrophic lateral sclerosis	9.1e-06	9.55e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.04e-06	9.49e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	8.67e-06	9.1e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.54e-06	8.96e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	8.53e-06	8.95e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.52e-06	8.94e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	8.51e-06	8.93e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.47e-06	8.89e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.38e-06	8.8e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.83e-06	8.22e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.82e-06	8.2e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.78e-06	8.17e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.68e-06	8.06e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	7.44e-06	7.8e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.42e-06	7.79e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.11e-06	7.46e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	7.06e-06	7.41e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	7.03e-06	7.37e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.99e-06	7.34e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	6.89e-06	7.23e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.82e-06	7.16e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	6.44e-06	6.76e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	6.44e-06	6.76e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.43e-06	6.75e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	6.4e-06	6.72e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.92e-06	6.22e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.91e-06	6.21e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	5.61e-06	5.89e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.59e-06	5.86e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.44e-06	5.71e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	5.29e-06	5.55e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.1e-06	5.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.02e-06	5.27e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.81e-06	5.05e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.57e-06	4.8e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	4.48e-06	4.7e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.41e-06	4.63e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.39e-06	4.61e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.2e-06	4.41e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.84e-06	4.04e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.79e-06	3.98e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.62e-06	3.8e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	3.46e-06	3.63e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.07e-06	3.22e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.37e-06	2.49e-05	CbGpPWpGaD
